PFNLive
FDA Review Backs Cornerstone Drug for Low Salt
Published: Tuesday, September 11th 2012
(Reuters) - A clinical reviewer from the U.S. Food and Drug Administration on Tuesday recommended the agency approve Cornerstone Therapeutics Inc's drug to treat low sodium levels due to a condition that causes the body to have excess water.
Cornerstone shares were up 5.4% at $6.61 in morning trading on Nasdaq.
Read more.
Comment(s)
Your comments are valuable to us. Thank you.
Related Articles
